Trevi Therapeutics (TRVI) announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC and expects to report topline data in the first quarter of 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics provides update on Haduvio’s clinical development program
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update
- Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress
- Trevi Therapeutics appoints James Cassella Chief Development Officer
- Trevi Therapeutics’ Haduvio shows cough relief efficacy in Phase 2a trial